The firm said CRISPR will enable targeted sequencing of long regions of interest that were previously only accessible with long-read whole-genome sequencing.
Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.
Infants born vaginally had gut microbiomes enriched with commensal bacteria, while those born by caesarian section harbored hospital-associated bacteria.
The industry organization issued a letter urging the agency to reconsider recent decisions to demand several laboratories stop offering pharmacogenetic testing.
Cantor Fitzgerald is the underwriter for the offering and is expected to be granted a 30-day option to purchase additional shares of HTG's common stock at the public offering price.
The Royal Oaks, Michigan-based firm anticipates launching the assay — which currently analyzes 214 genes for prostate cancer risk — for research-use-only applications in H2 2020.
Cantor Fitzgerald is the underwriter for the offering and is expected to be granted a 30-day option to purchase additional shares of HTG's common stock at the public offering price.
Cantor Fitzgerald is the underwriter for the offering and is expected to be granted a 30-day option to purchase additional shares of HTG's common stock at the public offering price.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
Join MNG Laboratories' Chief Medical Officer, Dr. Peter L. Nagy, and the Clinical Reporting Team as they present multiple case studies illustrating the value of using complementary testing and data analysis methods to increase the clinical sensitivity of MNG’s genetic testing portfolio. The team will highlight cases solved through the application of high resolution CNV assessment, mitochondrial DNA analysis, transcriptome/RNA sequencing, and repeat expansion screening from genome sequencing datasets. After the presentation, there will be a 15 minute Q&A with our speakers.
Join us for a webinar presented by our Chief Medical Officer, Dr. Peter L. Nagy, to discuss the benefits of performing and analyzing genome and RNA sequencing together. The increased number of single nucleotide and copy number variants associated with genome sequencing are best interpreted with the help of joint parental testing and the assessment of the functional significance of intronic and regulatory changes with a functional test like the transcriptome.
